Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 3/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.74 |
| ▸ | TTR | P02766 | 5/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.74 |
| ▸ | LMNA | P02545 | 4/20 | 0.74 |
| ▸ | MEN1 | O00255 | 3/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.74 |
| ▸ | TP53 | P04637 | 3/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.74 |
| ▸ | MAPT | P10636 | 3/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.74 |
| ▸ | HPGD | P15428 | 3/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.74 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.74 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.74 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL720794 | 1.00 | LCK (1.00) | LCKPTGS1TTRKDM4ELMNA | |
| Resveratrol SCHEMBL19425 | 0.86 | PTGS1 (1.00) | LCKPTGS1TTRKDM4ELMNA | |
| SCHEMBL1393726 | 0.86 | LCK (0.74) | LCKPTGS1TTRKDM4ELMNA | |
| Resveratrol SCHEMBL17629801 | 0.86 | PTGS1 (1.00) | LCKPTGS1TTRKDM4ELMNA | |
| SCHEMBL1393728 | 0.86 | LCK (0.74) | LCKPTGS1TTRKDM4ELMNA | |
| Resveratrol SCHEMBL19426 | 0.86 | PTGS1 (1.00) | LCKPTGS1TTRKDM4ELMNA | |
| Resveratrol SCHEMBL3704258 | 0.86 | PTGS1 (1.00) | LCKPTGS1TTRKDM4ELMNA | |
| Cis-Resveratrol SCHEMBL1931746 | 0.86 | PTGS1 (1.00) | LCKPTGS1TTRKDM4ELMNA | |
| Resveratrol SCHEMBL20164915 | 0.86 | PTGS1 (1.00) | LCKPTGS1TTRKDM4ELMNA | |
| Resveratrol SCHEMBL2300985 | 0.86 | PTGS1 (1.00) | LCKPTGS1TTRKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 329 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313010-A1 | COMPOUNDS FOR USE IN THE TREATMENT AND PREVENTION OF COVID- 19 | Szekeres, Thomas (AT) | 2024-02-07 | — | — | EP | claimed |
| WO-2022200086-A1 | COMPOUNDS FOR USE IN THE TREATMENT AND PREVENTION OF COVID- 19 | SZEKERES THOMAS (AT) | 2022-09-29 | — | — | WO | claimed |
| US-10723834-B1 | Low melting and low viscosity thermoset matrix resins from the Z configuration of polyhydroxy stilbenes | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2020-07-28 | — | — | US | claimed |
| US-9187591-B1 | Polyphenols and high-performance resins from syringaldehyde | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2015-11-17 | — | — | US | claimed |
| US-9127115-B1 | Polyphenols and high-performance resins from syringaldehyde | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2015-09-08 | — | — | US | claimed |
| US-9051414-B1 | Polyphenols and high-performance resins from syringaldehyde | The United States of America as Represented by the Secretary of he Navy (US) | 2015-06-09 | — | — | US | claimed |
| US-9018314-B1 | Polyphenols and high-performance resins from syringaldehyde | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2015-04-28 | — | — | US | claimed |
| US-8993688-B1 | Polyphenols and high-performance resins from syringaldehyde | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2015-03-31 | — | — | US | claimed |
| US-8993689-B1 | Polyphenols and high-performance resins from syringaldehyde | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2015-03-31 | — | — | US | claimed |
| US-20110105633-A1 | FUNCTIONALIZED STILBENE-POLYALKYLENE OXIDE PREPOLYMERS | PROMETHEAN SURGICAL DEVICES LLC (US) | 2011-05-05 | — | — | US | claimed |
| WO-2011049680-A1 | CRYOSENSITIZING AGENTS FOR ENHANCEMENT OF CRYOABLATION | BAUST JOHN M (US) | 2011-04-28 | — | — | WO | claimed |
| EP-1654210-B1 | STILBENE DERIVATIVES AND THEIR USE IN MEDICAMENTS | SZEKERES THOMAS (AT) | 2008-07-30 | — | — | EP | claimed |
| US-20070191627-A1 | Stilbene derivatives and their use in medicaments | SZEKERES THOMAS | 2007-08-16 | — | — | US | claimed |
| WO-2005102298-A1 | MEDICAL SUBSTANCE MIXTURES CONTAINING RESVERATROL OR RESVERATROL-DERIVATIVES, IN ADDITION TO THE USE THEREOF IN THE PRODUCTION OF MEDICAMENTS | SZEKERES THOMAS (AT) | 2005-11-03 | — | — | WO | claimed |
| US-6414038-B2 | A FORMULATION FOR REDUCING/PREVENTING GLYCATION OF PROTEINS OF SKIN AND/OR NAILS CONSISTS OF 3,3,5,5-TETRAHYDROXYSTILBENE COMPOUND OR O-ALKY OR O-ACYCL DERIVATIVES | SOCIETE L'OREAL (FR) | 2002-07-02 | — | — | US | claimed |
| US-20020028852-A1 | Resveratrol analogs for prevention of disease | RUTGERS, THE STATE UNIVERSITY | 2002-03-07 | — | — | US | claimed |
| US-20010025056-A1 | Hydroxystilbenes for reducing/inhibiting protein glycation and combating skin aging | SOCIETE L'OREAL S.A. (FR) | 2001-09-27 | — | — | US | claimed |
| EP-1110539-A1 | Use of 3,3',5,5'-tetrahehydroxystilbene as a glycation inhibitor | L'OREAL (FR) | 2001-06-27 | — | — | EP | claimed |
| EP-4313010-B1 | COMPOUNDS FOR USE IN THE TREATMENT AND PREVENTION OF COVID- 19 | SZEKERES THOMAS (AT) | 2025-02-19 | — | — | EP | disclosed |
| US-4118559-A | CNS AGENTS, ANALGESICS, TRANQUILIZERS | PFIZER INC. (US) | 1978-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010025056-A1 | Hydroxystilbenes for reducing/inhibiting protein glycation and combating skin aging | AGER, HMOX1, HAAO | LCK 1275/4885PTGS1 431/4885TTR 115/4885 |
| US-20070191627-A1 | Stilbene derivatives and their use in medicaments | PTGS2, PTGS1, PTGER2 | LCK 3040/4885PTGS1 2/4885TTR 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.